Structural Heart Devices Market to Grow from USD 12.94 Billion at a CAGR of 10.08% Through 2034

DelveInsight's "Structural Heart Devices Market" report offers an in-depth understanding of the global structural heart devices industry, covering market size, segmentation trends, regional dynamics, and competitive landscape through 2034.

To know in detail about the structural heart devices market outlook, segment-wise trends, and regional analysis, click here: https://www.delveinsight.com/report-store/structural-heart-devices-market-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Some of the Key Facts of the Structural Heart Devices Market Report
• In May 2026, Artivion, the parent company of JOTEC GmbH, completed its acquisition of Endospan for an upfront net purchase price of USD 135 million, adding the NEXUS Aortic Arch System to its structural and aortic repair portfolio.
• In February 2026, Valcare Medical announced the successful first U.S. transseptal implantation of its AMEND Transcatheter Mitral Valve Repair Annuloplasty System as part of its ongoing Early Feasibility Study.
• In April 2025, Edwards Lifesciences announced that its SAPIEN M3 transcatheter mitral valve replacement system received CE Mark approval for patients with moderate-to-severe or severe mitral regurgitation unsuitable for surgery or transcatheter edge-to-edge repair.
• In March 2025, Abbott announced new two-year results from its TRILUMINATE Pivotal trial, showing that the TriClip transcatheter edge-to-edge repair system provides significant and lasting improvement in tricuspid regurgitation.
• In 2024, Boston Scientific acquired Baylis Medical to strengthen its structural heart and transseptal access portfolio.
• In 2024 and 2025, Medtronic secured approvals and expanded commercial availability for its Evolut FX transcatheter aortic valve replacement system, improving deliverability and commissural alignment.

According to DelveInsight's analysis, the structural heart devices market is estimated at USD 12.94 billion in 2025 and is projected to reach USD 30.62 billion by 2034, growing at a CAGR of 10.08% during the forecast period from 2026 to 2034.
• North America dominated the global structural heart devices market revenue with a 50% share in 2025, representing the highest regional market share globally, while Asia-Pacific is the fastest-growing region.
• By product type, the replacement device segment dominated the market with a 63% share in 2025, driven by transcatheter aortic valve replacement becoming standard care across high-risk, intermediate-risk, and increasingly low-risk patients with severe aortic valve stenosis.
• By application, the atrial septal defect segment dominated with a 29% share in 2025, while aortic valve stenosis represents the largest single valvular disease burden globally, affecting an estimated 9 million people, and mitral regurgitation, affecting nearly 24 million people globally, is the fastest-growing application segment.
• By end-user, the hospital segment dominated with a 45% share in 2025, reflecting the concentration of advanced infrastructure, hybrid operating rooms, and highly skilled interventional cardiologists required for structural heart procedures.
• Congenital heart defects affect nearly 1% of all births in the United States, impacting approximately 40,000 babies each year, with about one in four of these infants requiring immediate intervention, while more than 5 million Americans are diagnosed with heart valve disease annually, with over 25,000 associated deaths.
• In the United Kingdom, heart valve disease affects 11.29% of individuals aged 65 and older, while in Australia, more than 500,000 individuals were diagnosed with heart valve disease in 2024, with an additional estimated 250,000 cases remaining undiagnosed.

Key Structural Heart Devices Companies
Medtronic, Boston Scientific, Braile Biomedica, JOTEC GmbH, Edwards Lifesciences, Valcare Medical, W. L. Gore & Associates, Abbott Laboratories, Cardiovascular Systems, XELTIS BV, and others.

Structural Heart Devices Market Overview
A structural heart device is a specialized medical technology designed to diagnose, repair, or replace abnormalities in the heart's structure, including its valves, chambers, walls, and associated vessels, treating both congenital defects, such as atrial septal defect and patent foramen ovale, and acquired valvular disorders, such as aortic valve stenosis and mitral regurgitation.
Treatment increasingly relies on catheter-based repair devices, including occluders, annuloplasty devices, and valvuloplasty devices, alongside surgical and transcatheter replacement devices, offering minimally invasive alternatives to open-heart surgery that reduce surgical trauma, shorten hospital stays, and expand treatment access to elderly and high-risk patients.
Despite strong momentum, the market faces constraints including frequent product failures and recalls undermining physician confidence, stringent regulatory requirements slowing innovation, and the high capital intensity of developing transcatheter platforms alongside the need for specialized hybrid operating rooms and highly trained interventional cardiologists.

Get a free sample for the Structural Heart Devices Market Forecast, Size & Share Analysis Report: https://www.delveinsight.com/report-store/structural-heart-devices-market-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Structural Heart Devices Market Segmentation
• Product Type: Repair Device (Occluders, Annuloplasty Devices, Valvuloplasty Devices, and Others) and Replacement Device (Mechanical Heart Valves and Tissue Heart Valves)
• Application: Atrial Septal Defect, Aortic Valve Stenosis, Patent Foramen Ovale, Ventricular Septal Defects, Mitral Regurgitation, and Others
• End-User: Hospital, Ambulatory Surgical Centers, and Others
• Geography: North America, Europe, Asia-Pacific, and Rest of World

Download the report to understand which factors are driving structural heart devices market trends: https://www.delveinsight.com/report-store/structural-heart-devices-market-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Structural Heart Devices Market Regional Insights
North America accounted for approximately 50% of the global structural heart devices market revenue in 2025, reflecting a mature interventional cardiology ecosystem, a strong clinical-research base, and a favorable regulatory environment supported by frequent FDA product approvals from leading manufacturers.
Europe is a large and advanced regional market, supported by established CE Mark regulatory pathways, strong government-backed reimbursement in Germany, France, and the United Kingdom, and a leading role in clinical research for next-generation mitral and tricuspid repair systems.
Asia-Pacific is the fastest-growing region, propelled by rising cardiovascular and valvular disease incidence, rapid infrastructure build-out, and growing healthcare investment across China, Japan, India, South Korea, and Australia, with regional players such as Microport, Meril Life Sciences, and Venus Medtech scaling local manufacturing capacity.

Discover more about the regional and segment-wise dynamics shaping the structural heart devices market: https://www.delveinsight.com/report-store/structural-heart-devices-market-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Structural Heart Devices Market Competitive Landscape
The structural heart devices market is classified as moderately consolidated. A group of global leaders with broad product portfolios and deep clinical evidence, including Medtronic, Edwards Lifesciences, Abbott, and Boston Scientific, anchors the top tier through robust transcatheter valve, repair, and occluder platforms, while specialized and fast-scaling providers such as Valcare Medical, XELTIS BV, JOTEC GmbH, Braile Biomedica, and W. L. Gore & Associates compete through focused technologies and niche clinical indications.
Investment in the structural heart devices ecosystem has concentrated on transcatheter mitral and tricuspid annuloplasty, restorative valve platforms, and next-generation occluder technology, with companies including Millipede, which has raised over USD 90 million for its IRIS Transcatheter Annuloplasty Ring, and Valcare Medical, which has raised more than USD 44 million to date, underscoring sustained investor conviction in transcatheter mitral repair.

Structural Heart Devices Market Drivers
• Rising global prevalence of cardiovascular and valvular disorders, including aortic stenosis, mitral regurgitation, and congenital heart defects.
• Continuous technological advancement in transcatheter platforms, including next-generation heart valves and mitral and tricuspid repair systems.
• Growing demand for minimally invasive cardiac interventions offering reduced surgical trauma and faster recovery.
• Regulatory approvals and expanding clinical indications, including CE Mark and FDA milestones for leading device platforms.
• Heavy capital investment and active M&A activity expanding device portfolios and manufacturing capacity.
• Aging global population and rising rates of hypertension, obesity, and diabetes increasing degenerative valvular disease incidence.

Structural Heart Devices Market Barriers
• Frequent product failures and recalls undermining physician confidence and disrupting treatment adoption.
• Stringent regulatory requirements, including extensive clinical trials and long evaluation timelines, slowing innovation.
• High capital intensity of developing and manufacturing transcatheter platforms.
• Need for specialized hybrid operating rooms, catheterization labs, and highly trained interventional cardiologists constraining adoption in lower-resourced healthcare systems.
• Reimbursement variability across geographies and cost pressures from tariffs on imported medical devices.

Scope of the Structural Heart Devices Market Report
• Study Period: 2023-2034
• Forecast Period: 2026-2034
• Regional Scope: North America, Europe, Asia-Pacific, and Rest of World
• Country Scope: United States, Canada, Mexico, Germany, United Kingdom, France, Italy, Spain, China, Japan, India, Australia, South Korea, and key countries
• Market Segmentation: Product type, application, end-user, and geography
• Market Dynamics: Detailed evaluation of market drivers, restraints, opportunities, and challenges
• Competitive Intelligence: Company profiles, recent M&A and licensing activity, product approvals, clinical trial results, and startup funding and investment trends

Contact Information
Company Name: DelveInsight Business Research LLP
Contact Person: Mehul Malhotra
Email: info@delveinsight.com
Phone: +1 469 945 7679
Address: 304 S. Jones Blvd #2432, Las Vegas, Nevada 89107, United States
Website: https://www.delveinsight.com/

About DelveInsight
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

This release was published on openPR.